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Summary
Background Seizures and their consequences contribute to the burden of epilepsy because they can cause health loss 
(premature mortality and residual disability). Data on the burden of epilepsy are needed for health-care planning and 
resource allocation. The aim of this study was to quantify health loss due to epilepsy by age, sex, year, and location 
using data from the Global Burden of Diseases, Injuries, and Risk Factors Study.
Methods We assessed the burden of epilepsy in 195 countries and territories from 1990 to 2016. Burden was measured 
as deaths, prevalence, and disability-adjusted life-years (DALYs; a summary measure of health loss defined by the sum 
of years of life lost [YLLs] for premature mortality and years lived with disability), by age, sex, year, location, and 
Socio-demographic Index (SDI; a compound measure of income per capita, education, and fertility). Vital registrations 
and verbal autopsies provided information about deaths, and data on the prevalence and severity of epilepsy largely 
came from population representative surveys. All estimates were calculated with 95% uncertainty intervals (UIs).
Findings In 2016, there were 45·9 million (95% UI 39·9–54·6) patients with all-active epilepsy (both idiopathic and 
secondary epilepsy globally; age-standardised prevalence 621·5 per 100 000 population; 540·1–737·0). Of these patients, 
24·0 million (20·4–27·7) had active idiopathic epilepsy (prevalence 326·7 per 100 000 population; 278·4–378·1). 
Prevalence of active epilepsy increased with age, with peaks at 5–9 years (374·8 [280·1–490·0]) and at older than 80 years 
of age (545·1 [444·2–652·0]). Age-standardised prevalence of active idiopathic epilepsy was 329·3 per 100 000 population 
(280·3–381·2) in men and 318·9 per 100 000 population (271·1–369·4) in women, and was similar among SDI quintiles. 
Global age-standardised mortality rates of idiopathic epilepsy were 1·74 per 100 000 population (1·64–1·87; 
1·40 per 100 000 population [1·23–1·54] for women and 2·09 per 100 000 population [1·96–2·25] for men). 
Age-standardised DALYs were 182·6 per 100 000 population (149·0–223·5; 163·6 per 100 000 population [130·6–204·3] 
for women and 201·2 per 100 000 population [166·9–241·4] for men). The higher DALY rates in men were due to higher 
YLL rates compared with women. Between 1990 and 2016, there was a non-significant 6·0% (–4·0 to 16·7) change in 
the age-standardised prevalence of idiopathic epilepsy, but a significant decrease in age-standardised mortality rates 
(24·5% [10·8 to 31·8]) and age-standardised DALY rates (19·4% [9·0 to 27·6]). A third of the difference in age-standardised 
DALY rates between low and high SDI quintile countries was due to the greater severity of epilepsy in low-income 
settings, and two-thirds were due to a higher YLL rate in low SDI countries.
Interpretation Despite the decrease in the disease burden from 1990 to 2016, epilepsy is still an important cause of 
disability and mortality. Standardised collection of data on epilepsy in population representative surveys will 
strengthen the estimates, particularly in countries for which we currently have no or sparse data and if additional data 
is collected on severity, causes, and treatment. Sizeable gains in reducing the burden of epilepsy might be expected 
from improved access to existing treatments in low-income countries and from the development of new effective 
drugs worldwide.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Epilepsy is a chronic disease of the CNS that affects 
individuals of all ages and has a worldwide distribution.1 
The cardinal manifestations of epilepsy are epileptic 
seizures: that is, recurrent paroxysmal events character­
ised by stereotyped behavioural alter ations reflecting the 
neural mechanisms involved in the epileptic process.2 
Several diseases and injuries are implicated in the origin 
of epileptic seizures, with variable distribution in the 
world.1 Although many underlying disease mechanisms 
can lead to epilepsy, the cause of the disease is still 
unknown in about 50% of global cases.1 The diagnosis 
of epileptic seizures and epilepsy and ascertainment of 
the cause are difficult tasks, especially in low­income 
countries where socio economic and cultural constraints 
are obstacles to the recognition and acceptance of the 
disease.3 These limitations, along with the differing 
distribution of some environmental risk factors, are 
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possible explanations for the heterogeneous frequency, 
course, and consequences of the disease in the world.4 
Causes of secondary epilepsy include, among others, 
stroke, neurodegenerative dis orders, infectious and 
inflammatory disorders, brain tumours, traumatic brain 
injuries, and congenital anomalies. However, these 
conditions were not considered risks in the Global 
Burden of Diseases, Injuries, and Risk Factors Study 
(GBD), but rather quantified as sequelae, or consequences, 
of the under lying causes of secondary epilepsy.
The recurrence of seizures and their physical and 
psychological consequences make epilepsy a burdensome 
neurological disorder. However, medical treatment of 
epilepsy with first­line antiepileptic drugs can render up 
to 70% of patients seizure free when adequately treated.5
According to a 2006 WHO report,5 50 million people 
had epilepsy. The proportion of all disability­adjusted 
life­years (DALYs) attributed to epilepsy was 0·5%, but 
these findings are no longer comparable to current GBD 
estimates because of major differences in assumptions 
underpinning the DALY implemented after the WHO 
report. Comparative findings from different countries 
are scarce, and meta­analyses of prevalence or incidence 
studies6–8 do not take time of study into account, do 
not use predictive covariates, and are unable to predict 
estimates by country.
The GBD collaboration provides a systematic, com­
parable method of quantifying health loss in detail by 
disease, age, sex, year, location, and sociodemographic 
status. In a recent GBD report9 on the burden of 
neurological diseases, idiopathic epilepsy (ie, epilepsy of 
genetic origin or without a definite structural, metabolic, 
infective, or immune cause) accounted for 5·0% of total 
neurological DALYs and 1·3% of all deaths. Globally, 
idiopathic epilepsy ranked fifth among neurological 
disorders after stroke, migraine, dementia, and menin­
gitis. Idiopathic epilepsy ranked second among neuro­
logical disorders in southern sub­Saharan Africa. When 
comparing the trends from 1990 to 2015, there was, 
however, a significant decrease in death and DALY rates 
attributable to idiopathic epilepsy, whereas the age­
standardised prevalence rate remained stable globally. A 
more detailed assessment of DALYs in each country and 
over time was thus needed to verify if and to what extent 
the overall trends can be confirmed at the country level 
and, where available, at the regional level to identify 
discrepancies and, consequently, areas of intervention. 
A detailed account of the GBD estimates for epilepsy 
Research in context
Evidence before this study
We searched PubMed, without language restrictions, using the 
terms (((((epilepsy AND epidemiology) AND 
(“2011/01/01”[PDat] : “2015/12/31”[PDat]))) AND ((epilepsy 
AND epidemiology)))) to identify articles published between 
Jan 1, 2011, and Oct 17, 2016. The 2015 estimates from the 
Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 
suggested that epilepsy contributes to 0·5% of 
disability-adjusted life-years (DALYs) due to all diseases and 
injuries and 5·0% of DALYs attributable to neurological disorders. 
However, these aggregated data do not explain in detail the 
burden due to epilepsy by age, sex, location, and socioeconomic 
status. For GBD 2016, we estimated global, regional, and 
country-specific prevalence, and years lived with disability for 
active epilepsy from 1990 to 2016. 317 studies on the prevalence 
of epilepsy, 81 studies on incidence, and 23 studies on mortality 
were selected on the basis of the quality of evidence. Additional 
studies on the severity of the disease were selected for the 
calculation of disability weights (appendix).
Added value of this study
This systematic analysis for GBD 2016 is specifically aimed at 
informing epilepsy researchers and clinicians who might not 
have seen the general publications on this global public health 
resource. We present results on the burden of active idiopathic 
epilepsy (ie, epilepsy of genetic or unknown origin), exploring 
variation by age, sex, location, and year, as well as the 
association between epilepsy burden and development status of 
a country, as measured by the Socio-demographic Index (SDI), 
a compound measure of income per capita, education, and 
fertility. About the same number of people globally have 
idiopathic and secondary epilepsy. There is little variation by SDI 
in prevalence of idiopathic epilepsy, with rates in the five SDI 
quintiles of countries indistinguishable from the global 
age-standardised rate of 326·7 per 100 000 population 
(278·4–378·1) in 2016. Two-thirds of the gap in burden from 
idiopathic epilepsy between SDI quintiles is due to longer 
survival in people with epilepsy, and another third is from lesser 
severity of disease in high SDI quintile countries.
Implications of all the available evidence
From 1990 to 2016, significant changes in the burden of 
idiopathic epilepsy have been observed. These changes resulted 
from reduction in the case fatality rate and severity of disease 
rather than a change in prevalence. The low mortality rate in 
high SDI countries suggests that further gains can still be made 
in low and middle SDI countries because deaths from idiopathic 
epilepsy are largely avoidable with adequate management of 
the disease. Similarly, improved access to treatment can reduce 
burden by shifting people with epilepsy out of the state of 
recurrent seizures. The causes of secondary epilepsy are more 
amenable to prevention; although treatments can lead to the 
same successful control of seizures, they have less successful 
treatment overall because they do not address the often-severe 
comorbid disabilities from motor or intellectual impairments. In 
future GBDs, it would be advisable to explicitly aggregate all of 
the causes of secondary epilepsy that are currently estimated as 
sequelae (consequences) of underlying diseases and often in 
combined sequelae with motor, cognitive, or sensory 
impairments.
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(including age­specific, sex­specific, time­specific, and 
geographical trends, and the sociodemographic context) 
was needed to make the information more accessible 
to researchers, clinicians, and planners of neurological 
services. We aimed to quantify health loss due to epilepsy 
by age, sex, year, and location using data from the 




Details of the general GBD methodology are reported in 
the appendix, including the guiding principles to assess 
health loss, the selection and assessment of the quality of 
the data sources, the input data and modelling strategies 
to assess epilepsy mortality and impairment, and a list of 
key articles used for reference.
Mortality
To assess premature mortality, we adhered to the 
underlying cause of death recorded in vital registration 
systems, as assigned by a physician on a death certificate. 
We made extensive corrections to cause of death data by 
redistributing deaths that were assigned to unspecified or 
intermediary causes on the basis of the International 
Classification of Diseases (ICD). The ICD­9 code for 
epilepsy is 345 and the ICD­10 codes for epilepsy are 
G40 and G41. Mortality from epilepsy was modelled 
with the Cause of Death Ensemble model, a tool devel­
oped for GBD cause of death analysis. The Cause of 
Death Ensemble model has the ability, through out­of­
sample predictive validity testing, to determine which 
combination of covariates produces estimates that best 
cover the input data. This approach is different from 
analyses done to prove causality between a covariate or 
risk and an out come. The data inputs in the model 
included 16 533 site­years of vital registration and 
1093 site­years of verbal autopsy data; a site­year is a 
unique combination of location and calendar year. The 
model also included predictive covariates on pigs per 
capita and pig meat consumption as a proxy for 
neurocysticercosis infection,10,11 systolic blood pressure, 
cholesterol,12 a measure of health­care access and quality,13 
and a summary exposure measure of alcohol con­
sumption.14 Additional details on calculations can be 
found in the GBD 2016 risk factor overview paper15 and in 
the appendix.
Non-fatal disease modelling
The reference definition for epilepsy was based on the 
International League Against Epilepsy (ILAE) Guidelines 
for Epidemiologic Studies on Epilepsy,16 which defined 
an epilepsy case as someone with an active, recurrent 
condition of epileptic seizures (two or more) unprovoked 
by an immediate cause and who has had at least 
one epileptic seizure in the past 5 years regardless of 
antiepileptic drug treatment.
Systematic review of the literature yielded 319 unique 
sources of data on prevalence covering 20 of the 21 world 
regions, 82 unique sources of data on incidence covering 
15 of the 21 world regions, and three unique sources of 
data on remission covering three of the 21 world regions. 
We also added 3 years of medical claims data from the 
USA. These data were defined in ICD­9 terms. The other 
sources of prevalence and incidence data were surveys 
stating case definitions independent of ICD codes.
Oceania was the only region for which no data were 
available. All data sources reported on all epilepsy 
(idiopathic and secondary combined). Where datapoints 
spanned an age group of more than 20 years, we split 
these data points into 5­year age bands by applying the 
age pattern from the USA, for which we had the most 
detailed data by age.
We modelled overall epilepsy prevalence and incidence 
using DisMod­MR 2.1, the Bayesian meta­regression tool 
developed for GBD. Study covariates were included to 
adjust US claims data to the reference epidemiological 
definition and to adjust studies with data on lifetime 
history of epilepsy to our active epilepsy definition. 
Additionally, we used a summary exposure measure 
of alcohol consumption and pig meat consumption 
per capita as predictive covariates on prevalence, as well 
as lag­distributed income as a predictive covariate on the 
excess mortality rate, or the excess rate of dying in cases 
of epilepsy in comparison with the general population.
Idiopathic and secondary epilepsy
The overall epilepsy prevalence derived from this model 
was split into idiopathic epilepsy (ie, epilepsy due to a 
genetic cause or when diagnostic assessment did not 
reveal a causative factor) and secondary epilepsy (ie, epi­
lepsy due to structural, metabolic, infective, or immune 
cause).
The term idiopathic is in accordance with the 
1985 ILAE proposal for classification of epilepsies and 
epileptic syndromes.17 Although this terminology has 
been questioned in the latest ILAE classification of the 
epilepsies,18 we retained the old term because most of 
the epidemiological studies used as data sources adopted 
the old classification.
From a systematic review, we identified 89 unique 
sources of data reporting on the proportion of epilepsy 
that is due to genetic or unknown causes, covering 18 of 
the 21 world regions. We found, however, that not all the 
sources identified used advanced diagnostic methods (CT 
or MRI scans in addition to electroencephalograms) to 
diagnose secondary epilepsy, and that sources that did not 
use advanced diagnostic methods reported systematically 
lower proportions for secondary epilepsy. Therefore, 
we added a covariate to adjust the studies with less 
comprehensive diagnostic procedures to those that used 
all available methods to diagnose secondary epilepsy. We 
used these data in a linear mixed­effects model, with fixed 
effects on under­5 mortality rate, log­transformed pig 
See Online for appendix
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Deaths Prevalence DALYs
2016 counts Percentage change in 
age-standardised rates, 
1990–2016
2016 counts Percentage change in 
age-standardised rates 
1990–2016
2016 counts Percentage change in 
age-standardised rates, 
1990–2016
Global 126 055 
(118 632 to 135 517)
–24·5% (–31·8 to –10·8) 23 962 448 
(20 401 828 to 27 737 043)
6·0% (–4·0 to 16·7) 13 492 251 
(11 014 685 to 16 503 078)
–19·4% (–27·6 to –9·0)
High SDI 12 744 
(12 203 to 13 558)
–2·7% (–7·2 to 4·8) 3 357 612 
(2 678 423 to 4 025 445)
10·6% (–11·6 to 39·1) 1 187 528 
(908 278 to 1 533 569)
–7·6% (–23·7 to 11·3)
High-middle SDI 10 938 
(10 194 to 12 003)
–39·2% (–45·8 to –27·6) 3 374 755 
(2 637 686 to 4 109 936)
3·0% (–19·6 to 34·0) 1 473 794 
(1 129 349 to 1 911 994)
–27·1% (–41·2 to –10·6)
Middle SDI 36 153 
(34 422 to 38 680)
–33·7% (–38·8 to –22·5) 7 864 730 
(6 633 313 to 9 248 943)
8·9% (–5·4 to 26·5) 4 145 107 
(3 342 749 to 5 089 933)
–23·0% (–31·3 to –13·6)
Low-middle SDI 48 802 
(43 507 to 55 892)
–30·6% (–40·3 to –13·5) 6 832 353 
(5 380 975 to 8 350 595)
1·6% (–19·3 to 26·1) 4 753 027 
(3 884 858 to 5 876 862)
–26·3% (–38·1 to –10·0)
Low SDI 17 360 
(15 695 to 19 187)
–12·1% (–23·3 to 10·3) 2 479 921 
(1 819 635 to 3 214 747)
4·5% (–24·9 to 45·4) 1 914 283 
(1 543 598 to 2 399 375)





–12·3% (–15·7 to –8·9) 1 266 669 
(990 026 to 1 532 133)
10·7% (–13·5 to 44·8) 403 536 
(290 787 to 546 430)
–3·0% (–23·2 to 23·5)
Canada 314 
(288 to 345)
–28·9% (–35·2 to –21·7) 84 838 
(21 473 to 147 748)
2·0% (–78·3 to 361·2) 30 135 
(14 286 to 58 457)
–17·0% (–67·4 to 105·8)
Greenland 2 
(1 to 2)
–29·9% (–46·7 to –6·0) 191 
(46 to 352)
–11·5% (–81·3 to 332·5) 110 
(64 to 181)
–29·1% (–65·5 to 44·6)
USA 2076 
(2002 to 2150)
–9·7% (–13·2 to –6·0) 1 181 207 
(927 479 to 1 429 263)
11·4% (–14·3 to 47·4) 373 183 
(265 183 to 509 146)
–1·7% (–23·1 to 26·6)
Australasia 346 
(319 to 375)
–15·1% (–22·6 to –7·0) 65 797 
(24 377 to 109 378)
–1·5% (–67·2 to 191·5) 27 725 
(16 880 to 47 808)
–18·3% (–56·9 to 55·2)
Australia 293 
(268 to 320)
–11·8% (–20·6 to –2·3) 55 674 
(14 413 to 97 939)
0·4% (–75·5 to 297·9) 23 141 
(12 914 to 42 582)
–16·0% (–60·8 to 84·8)
New Zealand 53 
(47 to 60)
–27·6% (–36·7 to –16·7) 10 123 
(2476 to 17 892)
–10·2% (–81·3 to 252·2) 4584 
(2628 to 8120)





–18·6% (–30·8 to –3·0) 364 894 
(264 943 to 478 045)
–0·4% (–30·7 to 48·0) 124 775 
(90 045 to 171 858)
–21·7% (–43·9 to 10·4)
Brunei 8 
(6 to 10)
–13·7% (–35·5 to 17·4) 1234 
(346 to 2090)
–15·7% (–79·5 to 258·1) 791 
(473 to 1262)
–18·8% (–57·8 to 70·1)
Japan 681 
(640 to 752)
–10·3% (–16·1 to –0·8) 247 249 
(196 541 to 306 896)
4·3% (–16·3 to 30·9) 75 644 
(54 202 to 102 261)
–11·4% (–29·4 to 9·5)
Singapore 16 
(13 to 20)
–28·4% (–43·1 to –9·0) 8590 
(2196 to 15 222)
1·9% (–73·7 to 272·6) 2666 
(1016 to 5160)
–24·6% (–72·5 to 99·8)
South Korea 535 
(389 to 705)
–30·0% (–49·6 to –5·1) 107 821 
(26 860 to 188 521)
–10·0% (–79·0 to 299·2) 45 674 
(23 369 to 79 779)
–35·8% (–71·4 to 47·8)
Western Europe 7842 
(7407 to 8435)
10·7% (4·4 to 20·0) 1 525 168 
(1 026 982 to 2 010 466)
12·0% (–25·7 to 74·4) 553 078 
(405 740 to 765 899)
–5·7% (–33·5 to 32·3)
Andorra 1 
(1 to 1)
–8·8% (–35·0 to 28·6) 237 
(61 to 411)
–8·9% (–77·0 to 347·6) 85 
(44 to 157)
–18·1% (–64·8 to 103·3)
Austria 88 
(78 to 99)
–12·1% (–23·0 to 0·4) 23 424 
(4812 to 42 084)
0·4% (–79·1 to 376·7) 8103 
(3579 to 16 383)
–18·6% (–68·8 to 100·3)
Belgium 282 
(248 to 321)
45·4% (27·5 to 66·5) 41 917 
(10 360 to 74 029)
12·5% (–76·6 to 397·1) 16 007 
(8515 to 28 340)
3·3% (–58·6 to 163·4)
Cyprus 8 
(7 to 9)
–30·0% (–40·6 to –12·9) 2314 
(513 to 4097)
–0·5% (–77·6 to 354·5) 811 
(354 to 1580)
–21·5% (–69·8 to 105·5)
Denmark 88 
(75 to 105)
38·6% (14·6 to 70·1) 14 926 
(4016 to 26 083)
9·2% (–73·7 to 380·3) 6187 
(3424 to 10 682)
4·1% (–54·7 to 144·9)
Finland 77 
(68 to 90)
–13·1% (–25·8 to 5·7) 14 276 
(3232 to 24 707)
2·4% (–79·8 to 416·5) 5809 
(3032 to 10 562)
–17·1% (–63·8 to 87·3)
France 1703 
(1542 to 1879)
4·9% (–5·4 to 16·7) 304 489 
(76 321 to 531 242)
11·7% (–75·2 to 413·6) 108 670 
(49 840 to 203 680)
–7·9% (–64·4 to 142·6)
Germany 2308 
(2062 to 2583)
51·6% (34·5 to 71·9) 429 396 
(109 560 to 761 662)
51·9% (–66·6 to 637·2) 153 712 
(70 909 to 296 374)
24·0% (–52·6 to 235·5)
Greece 75 
(68 to 84)
–9·7% (–20·0 to 2·0) 28 256 
(6981 to 49 284)
–0·2% (–77·4 to 315·3) 8753 
(3642 to 17 787)
–14·2% (–69·4 to 160·2)
(Table 1 continues on next page)
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Deaths Prevalence DALYs
2016 counts Percentage change in 
age-standardised rates, 
1990–2016
2016 counts Percentage change in 
age-standardised rates 
1990–2016
2016 counts Percentage change in 
age-standardised rates, 
1990–2016
(Continued from previous page)
Iceland 4 
(4 to 5)
45·8% (29·5 to 64·0) 908 
(250 to 1545)
3·7% (–74·0 to 297·5) 319 
(166 to 608)
–0·2% (–59·9 to 165·4)
Ireland 60 
(51 to 70)
–12·8% (–26·0 to 2·3) 13 153 
(3455 to 23 515)
1·0% (–75·6 to 379·3) 5231 
(2689 to 9628)
–14·4% (–63·9 to 107·9)
Israel 93 
(77 to 111)
20·8% (–3·3 to 47·2) 20 176 
(5762 to 33 993)
6·8% (–72·3 to 304·2) 8069 
(4125 to 14 281)
–1·1% (–56·0 to 132·1)
Italy 730 
(648 to 826)
11·4% (–1·2 to 28·2) 163 995 
(39 382 to 287 959)
–14·1% (–81·3 to 300·9) 52 778 
(23 068 to 104 089)
–23·8% (–75·4 to 131·9)
Luxembourg 11 
(10 to 13)
–0·9% (–15·2 to 16·2) 1813 
(463 to 3227)
–0·9% (–78·6 to 342·7) 719 
(401 to 1285)
–18·3% (–65·3 to 96·4)
Malta 4 
(3 to 5)
22·0% (–0·6 to 47·7) 1096 
(277 to 1967)
7·4% (–75·2 to 368·2) 385 
(172 to 751)
0·9% (–65·8 to 188·5)
Netherlands 268 
(240 to 299)
2·0% (–10·4 to 15·2) 51 678 
(12 813 to 90 495)
6·2% (–76·8 to 353·4) 18 951 
(9236 to 34 557)
–8·1% (–61·8 to 126·9)
Norway 79 
(70 to 90)
–17·3% (–28·7 to –3·8) 18 119 
(4897 to 30 666)
4·8% (–74·1 to 339·6) 6549 
(3270 to 12 227)
–16·6% (–65·3 to 100·0)
Portugal 169 
(152 to 190)
–15·9% (–25·7 to –4·1) 24 437 
(5590 to 43 209)
3·0% (–78·8 to 345·6) 10 049 
(5144 to 17 829)
–27·0% (–66·9 to 64·3)
Spain 452 
(405 to 515)
1·7% (–10·0 to 20·1) 105 520 
(26 203 to 187 007)
8·2% (–76·7 to 357·3) 33 847 
(15 438 to 67 771)
–14·5% (–70·6 to 131·2)
Sweden 111 
(98 to 126)
–20·5% (–30·5 to –8·9) 22 010 
(8669 to 35 691)
–8·7% (–67·2 to 164·7) 8370 
(4774 to 14 168)
–22·9% (–59·0 to 44·7)
Switzerland 107 
(84 to 134)
–40·3% (–53·9 to –22·9) 19 797 
(4601 to 35 373)
–8·0% (–80·3 to 272·2) 6923 
(3293 to 13 240)
–33·1% (–72·5 to 51·0)
UK 1123 
(1087 to 1172)
–6·9% (–10·5 to –2·3) 221 727 
(182 221 to 261 683)
–0·3% (–14·8 to 16·3) 92 400 
(74 455 to 114 293)





–19·7% (–29·4 to –8·2) 184 053 
(84 034 to 283 046)
1·8% (–57·6 to 140·4) 78 384 
(44 592 to 121 412)
–17·9% (–55·4 to 49·3)
Argentina 284 
(260 to 312)
–20·6% (–28·7 to –11·1) 101 909 
(27 878 to 174 824)
4·2% (–73·2 to 370·6) 44 400 
(19 443 to 83 007)
–13·2% (–64·2 to 116·1)
Chile 256 
(198 to 327)
–25·5% (–43·0 to –3·2) 71 432 
(16 341 to 124 915)
–2·6% (–81·3 to 264·9) 29 085 
(12 901 to 52 219)
–25·9% (–72·5 to 73·8)
Uruguay 52 
(47 to 56)
–3·1% (–14·0 to 8·1) 10 704 
(2755 to 18 961)
3·7% (–75·8 to 336·2) 4897 
(2428 to 8783)
–11·7% (–61·4 to 101·5)
Eastern Europe 1869 
(1512 to 2347)
–40·4% (–51·6 to –26·3) 431 632 
(174 470 to 721 540)
–7·0% (–64·1 to 149·9) 204 537 
(120 880 to 332 781)
–31·5% (–63·2 to 23·2)
Belarus 141 
(110 to 188)
–24·3% (–41·9 to 4·0) 21 987 
(4977 to 41 306)
–0·6% (–79·8 to 419·2) 12 079 
(6723 to 20 740)
–22·4% (–62·5 to 49·0)
Estonia 33 
(28 to 41)
–1·1% (–19·8 to 23·9) 3813 
(763 to 7187)
4·8% (–84·4 to 362·2) 2186 
(1365 to 3559)
–12·9% (–55·8 to 68·8)
Latvia 40 
(33 to 48)
21·0% (–1·0 to 48·1) 4820 
(939 to 9715)
–1·0% (–80·7 to 404·5) 2814 
(1745 to 4569)
–3·0% (–52·0 to 109·0)
Lithuania 63 
(56 to 72)
–12·8% (–22·8 to 0·1) 7858 
(1788 to 15 017)
0·2% (–79·9 to 371·3) 4587 
(2847 to 7865)
–15·0% (–56·3 to 70·0)
Moldova 68 
(59 to 79)
–37·9% (–47·5 to –25·6) 7935 
(1988 to 15 121)
–12·3% (–80·5 to 427·0) 5216 
(3364 to 8342)
–36·9% (–64·6 to 15·7)
Russia 882 
(636 to 1209)
–54·9% (–67·9 to –37·7) 288 899 
(57 036 to 544 297)
–8·7% (–83·1 to 404·8) 120 960 
(51 274 to 236 133)
–38·4% (–76·1 to 50·2)
Ukraine 642 
(464 to 886)
–10·9% (–36·6 to 25·5) 96 320 
(23 225 to 180 766)
–3·6% (–81·4 to 425·8) 56 695 
(31 720 to 96 555)
–14·6% (–58·1 to 83·5)
Central Europe 1848 
(1715 to 2013)
–14·6% (–21·3 to –4·5) 358 718 
(226 469 to 506 369)
7·2% (–35·7 to 81·3) 159 221 
(114 662 to 219 235)
–18·2% (–41·2 to 14·8)
Albania 53 
(45 to 64)
–11·3% (–25·4 to 8·7) 11 093 
(2563 to 21 126)
1·2% (–78·7 to 409·2) 5572 
(3040 to 9683)
–12·1% (–56·6 to 86·2)
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–39·8% (–50·9 to –26·5) 12 234 
(2827 to 22 374)
–1·6% (–79·3 to 393·9) 5630 
(3049 to 10 416)
–33·5% (–68·7 to 39·4)
Bulgaria 104 
(87 to 124)
–12·2% (–28·3 to 4·9) 22 376 
(4886 to 42 511)
6·3% (–76·1 to 457·1) 10 207 
(5062 to 19 113)
–12·1% (–63·3 to 96·7)
Croatia 86 
(74 to 100)
4·6% (–12·8 to 26·4) 12 506 
(2506 to 24 565)
–4·3% (–81·1 to 389·9) 5826 
(3282 to 10 581)
–16·0% (–62·5 to 88·9)
Czech Republic 136 
(123 to 156)
–26·2% (–34·8 to –13·0) 35 197 
(7181 to 67 984)
6·4% (–79·6 to 483·7) 12 989 
(6034 to 25 006)
–23·1% (–70·2 to 94·3)
Hungary 107 
(92 to 124)
–47·2% (–56·5 to –36·4) 30 177 
(5789 to 60 440)
–4·4% (–81·6 to 382·7) 11 631 
(5288 to 24 794)
–35·3% (–75·3 to 58·2)
Macedonia 25 
(22 to 27)
–32·3% (–41·4 to –22·9) 6373 
(1486 to 11 683)
7·2% (–77·8 to 429·8) 2649 
(1253 to 4923)
–23·1% (–70·2 to 79·9)
Montenegro 5 
(4 to 5)
–15·1% (–26·9 to –0·1) 1759 
(374 to 3471)
6·3% (–80·7 to 475·9) 626 
(252 to 1328)
–12·0% (–69·5 to 164·0)
Poland 690 
(599 to 789)
22·5% (5·1 to 45·3) 107 139 
(23 217 to 204 047)
19·6% (–79·0 to 515·2) 50 967 
(28 183 to 91 348)
–1·6% (–58·5 to 138·3)
Romania 266 
(235 to 304)
–33·6% (–42·2 to –24·0) 58 789 
(12 162 to 113 336)
0·5% (–78·7 to 569·3) 26 202 
(12 902 to 49 204)
–28·9% (–70·4 to 62·6)
Serbia 160 
(146 to 177)
–14·3% (–25·2 to –1·6) 34 026 
(8199 to 64 275)
16·9% (–76·3 to 496·4) 14 739 
(7484 to 28 301)
–10·2% (–62·6 to 111·3)
Slovakia 126 
(107 to 150)
–0·9% (–20·9 to 28·9) 20 226 
(4646 to 38 630)
10·2% (–77·4 to 484·7) 9933 
(5543 to 17 477)
–6·9% (–58·0 to 110·3)
Slovenia 23 
(20 to 27)
–53·1% (–61·4 to –42·4) 6822 
(1470 to 12 806)
–2·6% (–79·6 to 435·3) 2248 
(947 to 4645)
–36·0% (–76·8 to 79·3)
Central Asia 3225 
(2885 to 3659)
46·7% (31·6 to 66·6) 350 725 
(208 401 to 511 731)
18·0% (–33·0 to 107·2) 287 949 
(226 678 to 372 275)
23·4% (–6·4 to 68·1)
Armenia 17 
(15 to 20)
–63·6% (–68·6 to –57·5) 9642 
(2147 to 18 659)
7·4% (–80·0 to 426·4) 3662 
(1328 to 7284)
–33·7% (–78·5 to 69·4)
Azerbaijan 260 
(199 to 339)
11·3% (–14·8 to 46·7) 38 421 
(9 489 to 70 541)
25·5% (–72·4 to 632·8) 26 774 
(16 136 to 43 259)
6·8% (–45·2 to 110·0)
Georgia 40 
(33 to 48)
–52·6% (–61·5 to –42·8) 13 424 
(2705 to 25 872)
4·5% (–79·6 to 516·4) 6115 
(2517 to 11 647)
–28·7% (–72·9 to 60·9)
Kazakhstan 316 
(239 to 452)
–2·9% (–26·8 to 38·7) 61 571 
(13 281 to 121 213)
6·7% (–77·3 to 436·4) 36 654 
(18 495 to 65 154)
–3·3% (–57·4 to 111·4)
Kyrgyzstan 195 
(170 to 228)
3·6% (–10·1 to 21·7) 19 025 
(4001 to 38 756)
–10·6% (–82·7 to 339·0) 16 634 
(11 127 to 25 347)
–10·5% (–50·5 to 61·6)
Mongolia 83 
(64 to 100)
30·9% (–4·9 to 64·4) 11 107 
(2543 to 20 819)
43·6% (–69·2 to 612·1) 8087 
(5014 to 12 661)
22·8% (–37·7 to 151·2)
Tajikistan 398 
(318 to 514)
18·0% (–10·9 to 53·9) 32 028 
(6802 to 63 049)
–12·3% (–83·8 to 301·7) 34 022 
(23 148 to 48 864)
–1·3% (–43·4 to 69·4)
Turkmenistan 128 
(103 to 156)
2·5% (–17·3 to 26·4) 19 295 
(4266 to 38 101)
18·0% (–79·9 to 609·3) 14 218 
(8351 to 23 453)
1·6% (–51·6 to 111·9)
Uzbekistan 1789 
(1549 to 2031)
95·6% (69·9 to 125·7) 146 213 
(37 541 to 274 793)
34·2% (–69·2 to 435·2) 141 783 
(99 492 to 208 946)





–28·1% (–32·5 to –23·6) 1 361 130 
(1 015 253 to 1 743 102)
–6·2% (–31·2 to 27·6) 578 968 
(422 303 to 780 317)
–25·4% (–40·2 to –6·6)
Colombia 546 
(475 to 634)
–30·5% (–40·3 to –16·5) 259 714 
(59 331 to 473 541)
–3·8% (–79·7 to 313·9) 97 000 
(38 597 to 187 054)
–27·3% (–73·0 to 84·6)
Costa Rica 54 
(48 to 60)
–34·6% (–41·9 to –26·6) 24 952 
(7024 to 42 217)
5·3% (–75·9 to 366·3) 8491 
(3561 to 16 526)
–18·0% (–70·5 to 121·8)
El Salvador 64 
(55 to 75)
–35·8% (–46·5 to –17·9) 30 514 
(7543 to 51 484)
10·4% (–76·0 to 368·3) 11 761 
(4874 to 22 281)
–23·0% (–71·3 to 83·9)
Guatemala 360 
(280 to 449)
–16·0% (–36·6 to 7·3) 66 241 
(17 849 to 121 445)
4·6% (–74·5 to 403·8) 41 017 
(23 936 to 68 350)
–16·2% (–57·4 to 65·5)
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Honduras 202 
(144 to 284)
–22·9% (–44·2 to 5·9) 42 165 
(10 887 to 75 230)
–2·4% (–78·7 to 330·6) 23 578 
(12 269 to 39 543)
–20·8% (–65·5 to 70·6)
Mexico 1989 
(1903 to 2088)
–31·8% (–34·7 to –28·3) 727 028 
(558 990 to 909 062)
–8·7% (–31·6 to 23·5) 306 444 
(223 558 to 406 513)
–27·9% (–42·5 to –10·3)
Nicaragua 77 
(64 to 95)
–35·9% (–47·1 to –21·3) 29 296 
(8468 to 49 040)
–2·8% (–76·5 to 303·2) 12 233 
(5840 to 21 938)
–30·5% (–70·0 to 56·1)
Panama 54 
(46 to 64)
–10·3% (–25·6 to 8·8) 16 256 
(3819 to 29 184)
4·7% (–75·8 to 367·2) 6927 
(3242 to 12 790)
–9·7% (–63·2 to 116·6)
Venezuela 513 
(411 to 674)
–19·8% (–37·1 to 3·3) 164 964 
(44 841 to 291 195)
–6·0% (–77·9 to 313·9) 71 516 
(32 568 to 130 833)





–57·3% (–63·9 to –47·3) 261 097 
(115 128 to 404 582)
–5·3% (–58·0 to 110·2) 104 271 
(60 985 to 172 104)
–40·6% (–66·1 to 4·3)
Bolivia 172 
(138 to 212)
–51·3% (–63·8 to –31·8) 32 455 
(6889 to 64 243)
–25·0% (–84·6 to 268·8) 18 739 
(10 233 to 32 312)
–47·9% (–73·9 to 4·0)
Ecuador 248 
(222 to 277)
–54·6% (–59·9 to –49·0) 88 466 
(20 015 to 156 608)
–8·4% (–80·5 to 319·4) 38 919 
(17 712 to 70 540)
–38·8% (–74·8 to 34·2)
Peru 185 
(144 to 265)
–64·8% (–73·8 to –44·5) 140 175 
(32 569 to 254 196)
2·6% (–79·1 to 355·7) 46 613 
(16 342 to 97 928)
–39·8% (–80·6 to 58·6)
Caribbean 770 
(664 to 898)
–30·5% (–39·7 to –18·8) 136 726 
(82 218 to 192 747)
–7·5% (–48·4 to 59·4) 75 882 
(54 358 to 102 602)
–26·2% (–46·9 to 1·9)
Antigua and Barbuda 3 
(3 to 3)
–25·3% (–36·5 to –11·4) 428 
(116 to 720)
–5·6% (–77·8 to 327·8) 242 
(144 to 383)
–19·8% (–60·1 to 52·6)
The Bahamas 6 
(5 to 7)
–30·2% (–40·5 to –17·8) 1375 
(308 to 2506)
–8·1% (–80·6 to 282·8) 663 
(338 to 1162)
–26·2% (–69·2 to 60·6)
Barbados 6 
(6 to 7)
–23·3% (–34·2 to –9·7) 1075 
(284 to 1863)
0·1% (–75·6 to 340·1) 511 
(279 to 876)
–17·5% (–60·9 to 77·6)
Belize 7 
(6 to 8)
0·6% (–16·1 to 21·1) 1228 
(276 to 2240)
6·1% (–78·0 to 384·2) 724 
(410 to 1158)
–8·4% (–54·3 to 80·1)
Bermuda 1 
(1 to 1)
–57·6% (–64·9 to –48·6) 270 
(71 to 479)
–12·6% (–80·4 to 304·4) 86 
(35 to 168)
–44·2% (–79·4 to 42·1)
Cuba 95 
(85 to 106)
–34·1% (–41·7 to –24·0) 33 247 
(8371 to 57 987)
–0·8% (–76·3 to 312·7) 12 063 
(5352 to 22 358)
–23·4% (–70·1 to 78·6)
Dominica 3 
(3 to 4)
–12·4% (–24·8 to 3·3) 302 
(74 to 560)
–2·2% (–77·6 to 340·5) 217 
(137 to 331)
–9·3% (–48·3 to 63·3)
Dominican Republic 101 
(84 to 123)
–41·9% (–52·7 to –27·3) 31 056 
(7542 to 58 227)
4·9% (–78·7 to 450·1) 13 842 
(6180 to 25 438)
–27·6% (–71·2 to 71·8)
Grenada 3 
(2 to 4)
–3·1% (–22·7 to 19·1) 416 
(102 to 754)
3·0% (–76·8 to 352·5) 261 
(157 to 425)
–6·6% (–52·6 to 80·4)
Guyana 23 
(19 to 26)
–24·7% (–36·9 to –11·0) 2827 
(693 to 5043)
–1·1% (–76·9 to 336·1) 2013 
(1276 to 3014)
–20·5% (–55·1 to 40·1)
Haiti 345 
(235 to 479)
–29·6% (–47·7 to 4·1) 24 380 
(3980 to 56 714)
–15·2% (–88·4 to 494·0) 27 515 
(16 250 to 44 192)
–32·9% (–61·9 to 30·9)
Jamaica 52 
(42 to 66)
–28·0% (–43·6 to –5·5) 11 018 
(2808 to 19 011)
–3·6% (–75·9 to 283·8) 5336 
(2746 to 9348)
–22·9% (–63·2 to 62·5)
Puerto Rico 59 
(53 to 67)
–48·4% (–56·0 to –39·9) 14 581 
(3851 to 25 955)
–15·3% (–77·7 to 243·8) 5371 
(2676 to 9620)
–39·7% (–73·8 to 34·9)
Saint Lucia 5 
(5 to 6)
–35·0% (–42·7 to –27·0) 705 
(166 to 1278)
–7·1% (–80·1 to 405·7) 423 
(256 to 683)
–28·6% (–62·3 to 37·6)




–0·2% (–14·9 to 15·7) 428 
(99 to 764)
5·0% (–76·2 to 336·0) 291 
(181 to 457)
–4·4% (–47·1 to 77·4)
Suriname 15 
(14 to 18)
–13·8% (–25·7 to 0·6) 1920 
(403 to 3682)
–10·0% (–83·5 to 280·3) 1275 
(777 to 2038)
–21·0% (–57·9 to 50·0)
Trinidad and Tobago 39 
(34 to 45)
–23·2% (–34·6 to –10·7) 5970 
(1546 to 10 731)
–5·3% (–77·4 to 365·2) 3389 
(2012 to 5509)
–19·1% (–57·9 to 57·5)
Virgin Islands 2 
(2 to 2)
–25·0% (–43·3 to –2·9) 440 
(98 to 766)
–3·5% (–80·4 to 326·5) 176 
(81 to 322)
–20·8% (–66·7 to 83·7)
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–9·1% (–16·3 to –2·8) 848 153 
(609 618 to 1 089 267)
–4·9% (–35·4 to 38·3) 348 742 
(252 247 to 458 694)
–19·6% (–39·2 to 5·5)
Brazil 2495 
(2346 to 2680)
–9·3% (–16·6 to –3·0) 825 349 
(581 035 to 1 060 081)
–5·2% (–35·4 to 40·3) 337 631 
(242 624 to 446 686)
–19·9% (–40·1 to 6·4)
Paraguay 88 
(76 to 101)
–4·7% (–21·1 to 16·1) 22 804 
(5419 to 42 059)
7·8% (–78·1 to 442·9) 11 111 
(5491 to 20 340)
–5·7% (–61·4 to 128·1)
East Asia 13 613 
(12 795 to 15 210)
–55·8% (–59·9 to –47·8) 3 393 239 
(2 737 873 to 4 036 642)
5·8% (–15·8 to 33·3) 1 659 992 
(1 289 718 to 2 078 067)
–39·5% (–49·4 to –27·8)
China 12 779 
(11 966 to 14 361)
–57·3% (–61·5 to –49·3) 3 261 138 
(2 613 977 to 3 892 677)
5·6% (–16·7 to 34·4) 1 582 425 
(1 230 751 to 1 994 093)
–40·7% (–50·7 to –28·7)
North Korea 453 
(371 to 555)
13·7% (–14·3 to 43·8) 58 159 
(17 262 to 88 927)
3·2% (–71·2 to 297·4) 43 716 
(28 086 to 63 371)
4·6% (–39·9 to 94·0)




–32·5% (–45·5 to –10·8) 73 942 
(24 580 to 112 971)
17·5% (–65·4 to 281·0) 33 851 
(17 042 to 54 509)
–14·5% (–59·5 to 70·9)
Southeast Asia 9274 
(8359 to 9975)
–17·1% (–27·3 to –1·0) 2 476 546 
(1 936 233 to 3 038 069)
15·1% (–11·3 to 46·8) 1 339 006 
(1 008 109 to 1 733 718)
–6·1% (–23·3 to 15·3)
Cambodia 260 
(212 to 314)
–18·4% (–33·6 to 11·5) 58 844 
(17 847 to 97 084)
21·8% (–65·4 to 455·8) 36 251 
(19 511 to 58 011)
–7·7% (–54·5 to 91·0)
Indonesia 3260 
(2880 to 3616)
–11·4% (–24·8 to 4·8) 961 337 
(745 715 to 1 181 120)
20·5% (–8·3 to 62·4) 531 484 
(391 440 to 694 387)
–1·7% (–22·1 to 24·5)
Laos 134 
(96 to 178)
–19·0% (–37·8 to 16·6) 19 476 
(4652 to 34 802)
23·2% (–76·4 to 558·9) 16 126 
(8338 to 24 624)
–8·7% (–54·2 to 84·0)
Malaysia 253 
(228 to 284)
–22·3% (–34·1 to –4·9) 127 814 
(50 455 to 188 070)
13·5% (–58·2 to 230·4) 54 867 
(26 378 to 94 205)
–6·1% (–57·7 to 101·9)
Maldives 4 
(4 to 6)
–60·9% (–75·7 to –23·0) 1607 
(600 to 2315)
–11·5% (–67·5 to 139·3) 693 
(339 to 1158)
–50·0% (–76·3 to 9·3)
Mauritius 28 
(24 to 33)
–9·6% (–23·2 to 5·8) 6675 
(1953 to 9616)
11·7% (–66·7 to 216·8) 3376 
(1726 to 5297)
–3·7% (–52·8 to 77·9)
Myanmar 955 
(813 to 1175)
–21·7% (–37·2 to 3·4) 196 070 
(60 852 to 313 438)
13·2% (–67·1 to 309·7) 123 865 
(66 239 to 193 398)
–9·3% (–54·6 to 72·9)
Philippines 819 
(701 to 948)
–14·7% (–27·2 to –1·1) 345 441 
(95 379 to 570 826)
8·0% (–71·2 to 270·3) 176 577 
(75 952 to 305 773)
–3·7% (–59·3 to 113·4)
Sri Lanka 318 
(254 to 401)
–18·0% (–35·8 to 5·0) 124 196 
(54 642 to 164 196)
15·5% (–48·0 to 155·5) 51 538 
(27 088 to 81 058)
–6·5% (–52·0 to 76·9)
Seychelles 1 
(1 to 1)
–31·9% (–46·6 to –10·1) 444 
(156 to 649)
4·4% (–65·4 to 247·2) 199 
(93 to 333)
–16·9% (–64·1 to 77·2)
Thailand 693 
(598 to 792)
70·4% (25·2 to 110·8) 279 933 
(95 172 to 405 229)
22·5% (–59·5 to 223·8) 117 533 
(52 264 to 199 495)
12·8% (–50·7 to 160·4)
Timor-Leste 13 
(9 to 18)
–30·1% (–58·4 to 18·6) 3754 
(1026 to 6479)
25·7% (–67·2 to 467·8) 2211 
(1082 to 3631)
–13·7% (–59·4 to 90·1)
Vietnam 2537 
(2036 to 3035)
–29·5% (–44·6 to –3·9) 347 567 
(117 296 to 547 206)
5·6% (–68·4 to 266·5) 223 067 
(134 466 to 338 834)
–22·2% (–55·6 to 38·9)
Oceania 177 
(129 to 247)
5·6% (–12·0 to 26·8) 26 404 
(12 740 to 41 462)
7·5% (–51·7 to 142·9) 20 762 
(13 261 to 29 684)
5·2% (–31·7 to 68·3)
American Samoa 2 
(1 to 2)
101·3% (45·0 to 157·7) 302 
(99 to 451)
25·5% (–58·6 to 306·1) 186 
(111 to 277)
46·9% (–20·9 to 204·0)




7·1% (–25·9 to 48·3) 308 
(100 to 455)
8·6% (–65·3 to 279·6) 207 
(119 to 303)
2·0% (–44·5 to 91·7)
Fiji 21 
(15 to 26)
2·8% (–26·8 to 46·8) 2990 
(1046 to 4590)
5·5% (–69·5 to 228·8) 2307 
(1472 to 3329)
5·1% (–41·4 to 85·0)
Guam 1 
(1 to 1)
51·5% (20·8 to 92·8) 516 
(166 to 807)
10·3% (–66·6 to 290·6) 234 
(105 to 394)
17·6% (–50·1 to 224·1)
Kiribati 4 
(3 to 5)
4·1% (–15·9 to 30·0) 342 
(94 to 562)
6·1% (–73·0 to 305·4) 382 
(262 to 526)
2·5% (–37·7 to 61·3)
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Marshall Islands 1 
(1 to 1)
14·4% (–13·8 to 45·1) 207 
(74 to 322)
9·7% (–66·1 to 284·3) 143 
(84 to 220)





0·6% (–26·9 to 38·8) 355 
(120 to 543)
1·8% (–68·0 to 221·1) 151 
(66 to 262)
–7·8% (–64·3 to 127·4)
Papua New Guinea 128 
(83 to 192)
2·5% (–19·3 to 31·3) 16 671 
(4342 to 30 406)
11·5% (–73·5 to 415·7) 14 271 
(7770 to 22 092)
4·9% (–46·0 to 111·0)
Samoa 2 
(2 to 3)
–2·6% (–23·7 to 24·1) 586 
(197 to 869)
7·7% (–67·0 to 227·1) 318 
(168 to 497)
–2·4% (–49·8 to 87·1)
Solomon Islands 11 
(7 to 15)
22·5% (–6·7 to 62·6) 1599 
(485 to 2499)
14·0% (–63·3 to 321·0) 1249 
(723 to 1808)
16·1% (–34·6 to 115·9)
Tonga 1 
(1 to 1)
–2·9% (–25·7 to 29·8) 295 
(88 to 453)
7·7% (–68·6 to 234·5) 143 
(68 to 236)
1·0% (–53·6 to 130·5)
Vanuatu 5 
(4 to 7)
22·0% (–3·9 to 58·6) 689 
(186 to 1134)
11·8% (–72·8 to 317·5) 550 
(330 to 814)
17·2% (–36·7 to 123·7)




–29·0% (–38·5 to –7·2) 2 085 190 
(1 585 837 to 2 583 210)
0·6% (–25·8 to 35·4) 1 112 639 
(835 154 to 1 428 785)
–22·0% (–39·3 to –0·2)
Afghanistan 997 
(462 to 1585)
–5·0% (–20·6 to 20·1) 81 796 
(16 564 to 158 200)
8·6% (–78·5 to 478·8) 95 821 
(47 566 to 151 640)
–3·5% (–42·3 to 81·1)
Algeria 440 
(348 to 574)
–27·3% (–44·5 to –4·7) 143 986 
(52 342 to 210 520)
–0·8% (–64·0 to 192·9) 72 891 
(36 536 to 115 429)
–20·3% (–61·6 to 56·4)
Bahrain 19 
(15 to 23)
–21·7% (–39·2 to 3·2) 5371 
(1861 to 7938)
0·2% (–68·2 to 224·9) 2550 
(1356 to 4155)
–19·9% (–63·7 to 73·3)
Egypt 498 
(389 to 657)
–30·2% (–44·3 to –8·9) 347 306 
(119 883 to 516 249)
22·6% (–62·8 to 261·1) 154 089 
(64 781 to 263 047)
–4·2% (–62·7 to 113·6)
Iran 765 
(627 to 937)
–29·3% (–46·3 to –3·1) 344 959 
(114 307 to 517 959)
18·1% (–64·5 to 290·2) 153 434 
(74 033 to 259 394)
–13·6% (–63·1 to 77·5)
Iraq 506 
(388 to 632)
–13·6% (–37·5 to 14·7) 148 451 
(47 636 to 224 948)
7·8% (–66·0 to 247·4) 82 976 
(43 353 to 132 061)
–6·7% (–57·2 to 74·2)
Jordan 62 
(48 to 78)
–28·9% (–46·4 to –1·6) 28 226 
(10 556 to 40 921)
1·4% (–63·0 to 171·4) 12 215 
(6260 to 20 483)
–19·3% (–61·6 to 71·7)
Kuwait 22 
(17 to 29)
–16·7% (–37·9 to 8·8) 13 410 
(4695 to 20 390)
7·2% (–66·0 to 260·3) 5018 
(2149 to 8992)
–10·5% (–65·7 to 119·0)
Lebanon 41 
(30 to 56)
–52·1% (–66·7 to –24·3) 18 771 
(5963 to 29 876)
0·7% (–71·5 to 284·7) 7294 
(3284 to 13 335)
–32·8% (–73·5 to 56·8)
Libya 65 
(52 to 78)
–19·1% (–31·5 to –1·2) 17 003 
(6200 to 25 165)
1·0% (–65·1 to 222·5) 8743 
(4887 to 13 833)
–16·6% (–56·9 to 70·7)
Morocco 923 
(471 to 1887)
–18·0% (–40·4 to 16·7) 131 484 
(39 352 to 202 772)
–3·2% (–74·9 to 192·2) 91 536 
(39 622 to 153 483)
–19·5% (–61·6 to 41·9)
Oman 37 
(30 to 45)
–39·8% (–53·6 to –15·7) 16 113 
(5483 to 23 524)
0·1% (–67·2 to 210·3) 6815 
(3194 to 11 719)
–24·3% (–67·9 to 56·0)
Palestine 99 
(87 to 118)
–18·6% (–32·8 to –0·3) 20 243 
(7532 to 30 109)
–7·8% (–66·8 to 165·2) 12 442 
(7685 to 18 403)
–22·8% (–54·3 to 33·5)
Qatar 11 
(8 to 15)
–65·9% (–75·6 to –51·7) 7472 
(2440 to 11 236)
–16·1% (–72·7 to 167·5) 2720 
(1211 to 4856)
–42·9% (–77·5 to 31·0)
Saudi Arabia 211 
(182 to 253)
–35·2% (–47·6 to –11·9) 101 825 
(72 566 to 131 166)
9·3% (–23·9 to 62·4) 40 602 
(28 238 to 56 390)
–20·9% (–43·3 to 11·1)
Sudan 630 
(417 to 899)
–23·5% (–40·7 to 7·9) 100 884 
(25 304 to 177 328)
8·9% (–74·7 to 394·6) 78 885 
(42 112 to 123 911)
–15·8% (–54·6 to 82·0)
Syria 83 
(71 to 95)
–32·0% (–45·1 to –3·3) 63 970 
(19 973 to 97 795)
11·6% (–64·7 to 268·7) 24 507 
(9115 to 44 697)
–12·8% (–65·3 to 104·3)
Tunisia 112 
(81 to 149)
–33·1% (–47·5 to –10·3) 33 543 
(11 913 to 49 929)
8·2% (–64·4 to 205·7) 16 040 
(8153 to 26 700)
–21·0% (–62·4 to 47·8)
Turkey 1316 
(1106 to 1544)
–47·9% (–61·7 to –12·9) 345 186 
(134 469 to 493 338)
–18·4% (–70·2 to 127·0) 171 537 
(97 074 to 267 928)
–43·5% (–71·0 to 8·2)
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United Arab Emirates 115 
(82 to 151)
–20·3% (–41·7 to 11·8) 34 858 
(12 413 to 52 207)
–1·3% (–67·5 to 228·3) 17 172 
(9213 to 27 895)
–19·1% (–64·9 to 82·4)
Yemen 404 
(274 to 568)
–26·8% (–42·5 to 6·5) 78 302 
(21 865 to 132 676)
7·3% (–73·0 to 426·7) 54 652 
(29 282 to 85 361)
–19·6% (–58·3 to 63·3)
South Asia 43 009 
(39 131 to 47 849)
–33·0% (–42·2 to –15·9) 5 272 409 
(4 221 404 to 6 351 648)
–1·9% (–22·0 to 23·9) 3 697 849 
(3 076 577 to 4 457 900)
–31·7% (–43·1 to –15·6)
Bangladesh 4449 
(3565 to 5648)
–55·3% (–66·6 to –37·3) 530 689 
(176 781 to 816 118)
–18·2% (–74·5 to 194·1) 395 800 
(265 827 to 558 704)
–48·5% (–68·3 to –17·6)
Bhutan 18 
(13 to 24)
–44·3% (–60·2 to –16·7) 2808 
(909 to 4471)
–7·1% (–70·5 to 250·4) 1764 
(1061 to 2612)
–40·2% (–66·3 to 2·9)
India 34 253 
(31 149 to 37 749)
–31·4% (–40·7 to –13·5) 3 934 737 
(3 176 019 to 4 766 534)
–1·9% (–20·1 to 21·4) 2 806 946 
(2 338 317 to 3 399 136)
–31·7% (–43·0 to –14·9)
Nepal 709 
(565 to 896)
–31·6% (–50·0 to –6·7) 113 530 
(35 311 to 174 642)
11·7% (–65·0 to 341·8) 68 811 
(42 894 to 102 692)
–28·2% (–59·6 to 24·0)
Pakistan 3580 
(2853 to 4286)
–8·9% (–27·8 to 13·4) 690 645 
(204 907 to 1 169 829)
9·5% (–69·4 to 412·5) 424 529 
(249 368 to 664 059)





–5·1% (–18·2 to 9·1) 383 628 
(280 596 to 496 987)
1·4% (–30·4 to 45·5) 389 805 
(331 721 to 457 948)
–8·0% (–21·3 to 7·6)
Botswana 171 
(76 to 271)
1·8% (–48·5 to 65·0) 13 791 
(4748 to 21 418)
13·7% (–63·1 to 317·0) 12 454 
(7049 to 18 844)
1·5% (–41·2 to 67·0)
Lesotho 199 
(143 to 261)
30·6% (–21·2 to 90·3) 7471 
(1509 to 14 829)
30·5% (–81·0 to 734·2) 12 171 
(8310 to 16 454)
33·3% (–23·9 to 118·8)
Namibia 159 
(101 to 234)
–20·9% (–44·3 to 5·8) 11 753 
(3202 to 20 350)
–2·9% (–73·6 to 308·6) 11 283 
(6576 to 17 192)
–20·1% (–49·7 to 27·1)
South Africa 4429 
(4005 to 4946)
–12·1% (–25·4 to 2·6) 294 658 
(203 182 to 388 082)
0·6% (–34·5 to 54·8) 296 686 
(248 902 to 352 893)
–13·3% (–28·3 to 3·7)
Swaziland 100 
(67 to 138)
5·2% (–27·0 to 43·9) 6593 
(1618 to 11 383)
9·8% (–71·4 to 356·8) 7357 
(4722 to 10 646)
8·0% (–31·1 to 60·3)
Zimbabwe 635 
(509 to 780)
81·5% (34·3 to 206·5) 49 362 
(12 760 to 87 483)
4·7% (–75·1 to 314·2) 49 854 
(34 019 to 70 851)




(6967 to 11 218)
7·3% (–7·6 to 24·3) 1 376 947 
(760 842 to 2 178 156)
7·1% (–43·9 to 123·2) 1 010 670 
(715 404 to 1 435 946)
–1·2% (–30·4 to 44·9)
Benin 274 
(229 to 327)
42·0% (17·1 to 73·8) 51 645 
(11 420 to 99 962)
13·0% (–75·5 to 512·1) 34 894 
(18 694 to 59 815)
15·1% (–47·3 to 157·1)
Burkina Faso 395 
(328 to 480)
–7·7% (–25·2 to 16·6) 49 576 
(7985 to 120 431)
1·4% (–84·7 to 617·9) 44 226 
(25 505 to 74 362)
–8·2% (–54·4 to 96·0)
Cameroon 663 
(467 to 897)
63·2% (24·4 to 105·8) 107 383 
(20 059 to 229 080)
22·6% (–80·9 to 661·1) 77 901 
(40 785 to 136 899)
31·8% (–40·1 to 213·4)
Cape Verde 17 
(14 to 22)
–4·0% (–28·7 to 29·4) 3383 
(911 to 5671)
15·8% (–72·4 to 389·1) 1882 
(1033 to 3162)
–2·5% (–51·1 to 92·8)
Chad 357 
(274 to 435)
48·8% (22·6 to 82·5) 44 949 
(7136 to 105 860)
24·8% (–83·8 to 805·7) 39 677 
(22 087 to 68 741)
31·4% (–39·9 to 195·5)
Côte d’Ivoire 693 
(535 to 855)
60·0% (31·0 to 93·5) 81 378 
(18 215 to 168 075)
18·7% (–76·2 to 478·1) 68 594 
(41 257 to 110 732)
29·9% (–34·5 to 164·5)
The Gambia 38 
(30 to 47)
39·8% (15·1 to 68·7) 8257 
(2371 to 13 718)
11·6% (–69·4 to 334·0) 5113 
(2874 to 8091)
10·5% (–43·6 to 131·6)
Ghana 411 
(342 to 491)
46·2% (17·0 to 88·0) 137 757 
(34 782 to 240 697)
25·9% (–71·4 to 439·9) 70 879 
(30 793 to 125 142)
17·6% (–53·6 to 214·1)
Guinea 321 
(264 to 382)
45·4% (17·4 to 79·4) 40 317 
(7713 to 89 091)
8·7% (–81·2 to 651·8) 33 725 
(19 721 to 57 367)
14·3% (–43·6 to 149·4)
Guinea-Bissau 64 
(48 to 78)
36·4% (9·4 to 71·2) 4710 
(762 to 12 028)
15·1% (–84·8 to 848·2) 5344 
(3332 to 8534)
18·0% (–39·0 to 144·5)
Liberia 95 
(78 to 116)
34·2% (10·5 to 64·7) 20 420 
(4697 to 41 125)
1·1% (–81·3 to 366·6) 12 594 
(6363 to 22 215)
–0·8% (–58·4 to 133·0)
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Mali 377 
(284 to 473)
14·5% (–16·4 to 58·1) 41 309 
(5316 to 98 257)
28·9% (–82·0 to 861·8) 37 675 
(21 041 to 62 799)
7·0% (–48·0 to 106·9)
Mauritania 73 
(48 to 105)
14·0% (–20·4 to 64·7) 22 889 
(6600 to 37 382)
8·7% (–72·5 to 300·4) 12 189 
(5764 to 20 521)
0·8% (–55·5 to 134·5)
Niger 451 
(352 to 551)
28·3% (–4·4 to 79·2) 59 803 
(11 391 to 127 616)
12·6% (–81·0 to 599·0) 49 820 
(27 853 to 82 354)
6·7% (–48·8 to 119·6)
Nigeria 3772 
(2141 to 6507)
–17·0% (–42·6 to 13·9) 577 948 
(92 319 to 1 265 749)
–2·8% (–85·1 to 499·3) 428 168 
(193 932 to 775 350)
–17·2% (–65·2 to 73·0)




25·2% (–5·2 to 59·3) 1050 
(324 to 1684)
17·0% (–67·6 to 374·3) 568 
(272 to 935)
8·7% (–50·9 to 147·3)
Senegal 378 
(327 to 435)
45·1% (23·7 to 68·7) 74 912 
(19 138 to 127 400)
10·4% (–72·3 to 296·9) 49 079 
(27 383 to 77 078)
13·1% (–43·3 to 130·2)
Sierra Leone 162 
(122 to 200)
38·6% (16·3 to 67·4) 18 035 
(2960 to 42 479)
13·7% (–85·1 to 776·9) 16 196 
(9012 to 28 000)
15·5% (–45·2 to 138·6)
Togo 188 
(156 to 221)
46·1% (19·8 to 72·7) 31 210 
(6230 to 61 789)
–5·3% (–81·8 to 435·8) 22 142 
(11 885 to 36 811)





–24·7% (–37·1 to –2·9) 1 520 535 
(1 028 359 to 2 024 454)
2·5% (–32·9 to 55·0) 1 058 588 
(823 366 to 1 353 425)
–17·6% (–36·3 to 9·3)
Burundi 279 
(225 to 342)
–26·0% (–44·5 to 11·7) 41 575 
(8444 to 79 189)
–5·5% (–83·7 to 405·0) 32 995 
(18 709 to 53 315)
–21·6% (–60·2 to 58·3)
Comoros 18 
(14 to 22)
–22·7% (–41·4 to 3·8) 3500 
(1038 to 5908)
–7·3% (–76·4 to 254·9) 2307 
(1302 to 3569)
–21·3% (–60·0 to 51·1)
Djibouti 24 
(18 to 32)
–9·2% (–34·9 to 20·5) 4357 
(1068 to 7626)
1·9% (–75·7 to 374·4) 2979 
(1600 to 4730)
–8·9% (–55·4 to 84·2)
Eritrea 134 
(105 to 162)
–21·8% (–41·8 to 7·6) 20 890 
(4835 to 37 975)
2·4% (–77·7 to 364·6) 15 943 
(8712 to 25 452)
–14·8% (–56·7 to 60·8)
Ethiopia 2671 
(2124 to 3239)
–42·3% (–59·0 to –12·7) 371 758 
(106 621 to 596 895)
–5·8% (–75·4 to 300·5) 286 989 
(175 383 to 427 015)
–35·3% (–65·0 to 20·3)
Kenya 554 
(434 to 680)
–1·6% (–17·4 to 17·4) 200 780 
(160 992 to 244 896)
4·1% (–12·1 to 26·9) 102 527 
(76 594 to 132 453)
–3·5% (–17·6 to 12·4)
Madagascar 560 
(430 to 711)
–13·3% (–32·9 to 14·5) 79 682 
(17 696 to 150 960)
–4·3% (–81·3 to 392·8) 62 449 
(36 885 to 100 163)
–14·3% (–56·8 to 67·4)
Malawi 431 
(322 to 551)
–9·7% (–35·3 to 25·9) 55 657 
(11 206 to 114 932)
2·2% (–83·0 to 473·1) 45 071 
(26 037 to 72 907)
–11·0% (–55·8 to 77·1)
Mozambique 508 
(386 to 691)
–22·9% (–42·1 to 4·6) 112 389 
(19 239 to 231 743)
16·1% (–79·8 to 499·2) 73 287 
(34 697 to 129 718)
–9·4% (–61·6 to 104·0)
Rwanda 246 
(201 to 301)
–26·1% (–48·0 to 19·5) 51 061 
(12 640 to 87 890)
8·5% (–74·4 to 413·2) 32 509 
(17 651 to 51 320)
–18·2% (–60·4 to 80·0)
Somalia 304 
(224 to 384)
–10·4% (–29·6 to 15·3) 28 138 
(4753 to 60 869)
4·5% (–84·1 to 694·3) 28 857 
(16 599 to 45 466)
–8·5% (–51·5 to 79·8)
South Sudan 298 
(224 to 386)
0·4% (–23·3 to 33·8) 35 504 
(6002 to 80 778)
3·3% (–84·5 to 623·6) 31 096 
(17 753 to 53 863)
–3·0% (–52·8 to 110·0)
Tanzania 1162 
(966 to 1393)
–18·5% (–35·2 to 3·9) 246 202 
(54 678 to 428 813)
6·2% (–75·5 to 380·8) 155 696 
(85 488 to 249 855)
–10·8% (–56·1 to 82·6)
Uganda 936 
(783 to 1112)
–11·5% (–29·3 to 19·2) 194 280 
(41 805 to 383 272)
5·1% (–80·2 to 434·2) 130 523 
(67 857 to 222 380)
–5·2% (–55·9 to 119·1)
Zambia 455 
(316 to 621)
24·2% (–15·6 to 67·9) 73 796 
(15 706 to 137 808)
13·0% (–76·4 to 521·1) 54 989 
(29 577 to 89 152)





–13·8% (–30·3 to 12·8) 272 787 
(113 188 to 480 953)
3·7% (–59·6 to 162·7) 253 362 
(171 108 to 371 268)
–11·5% (–41·2 to 42·1)
Angola 530 
(384 to 706)
–18·9% (–47·3 to 36·2) 71 859 
(13 396 to 143 895)
6·6% (–80·3 to 474·3) 61 288 
(35 567 to 96 825)





–0·5% (–20·8 to 25·5) 7078 
(1005 to 18 481)
–0·7% (–86·4 to 827·7) 11 901 
(6419 to 19 191)
–2·1% (–40·9 to 65·6)
(Table 1 continues on next page)
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Congo (Brazzaville) 97 
(70 to 126)
–24·7% (–45·7 to 13·0) 14 479 
(3508 to 26 699)
–5·3% (–79·0 to 341·4) 11 085 
(6355 to 17 066)





–11·1% (–30·4 to 13·5) 170 264 
(31 635 to 351 352)
3·5% (–79·9 to 522·2) 163 335 
(98 089 to 259 549)
–9·2% (–50·2 to 74·1)
Equatorial Guinea 11 
(7 to 17)
–56·9% (–77·8 to –4·5) 2558 
(528 to 5136)
30·6% (–75·4 to 554·1) 1514 
(694 to 2629)
–36·3% (–74·1 to 55·5)
Gabon 34 
(26 to 45)
–16·4% (–40·1 to 19·8) 6549 
(1594 to 11 829)
–0·9% (–75·6 to 267·2) 4238 
(2322 to 6845)
–14·3% (–58·7 to 69·5)
95% uncertainty intervals are in parentheses. DALYs=disability-adjusted life-years. SDI=Socio-demographic Index.
Table 1: Deaths, prevalence, and DALYs for idiopathic epilepsy in 2016, and percentage change in age-standardised rates by location
meat consumption, access to sanitation, and the study 
quality covariate, as well as random effects for super­
regions (ie, seven aggregates of 21 world regions defined 
in GBD). We obtained predictions for the proportion of 
idiopathic epilepsy from this model for every location and 
year, and applied them to the preva lence and incidence 
results of the DisMod­MR 2.1 model to calculate the 
prevalence and incidence of idiopathic epilepsy.
Secondary epilepsy was quantified as long­term con­
sequences of meningitis, tetanus, malaria, cysticercosis, 
cystic echinococcosis, preterm birth complications, neo­
natal encephalopathy, neonatal sepsis, and neonatal 
haemolytic disease. Secondary epilepsy from other causes, 
such as brain cancer, traumatic brain injury, congenital 
anomalies, or stroke, was not quantified explicitly but 
assumed to be subsumed in the severity distributions and 
corresponding disability weights for those conditions.19
Severity distributions and years lived with disability
Three health states were defined as sequelae of idiopathic 
epilepsy: severe epilepsy, defined as an average seizure 
frequency of more than or equal to once per month; less 
severe epilepsy with a seizure frequency of less than once 
a month, or no seizures in the past year while untreated 
but still fulfilling the criteria of active epilepsy; and 
seizure­free, treated epilepsy, defined as not having 
seizures in the past year while on treatment. All the data 
informing these splits were identified through systematic 
review. The data included 29 unique sources on the 
proportion of epilepsy that is severe, covering 12 of the 
21 world regions; 68 unique sources on the proportion of 
epilepsy that is treated, covering 16 of the 21 world 
regions; and ten unique sources on the proportion of 
treated patients with epilepsy who do not have seizures, 
covering six of the 21 world regions. The distributions of 
cases across these three health states were quantified in 
three additional linear models. The first two splits, to 
derive the proportion of less severe epilepsy and then to 
calculate the proportion of less severe epilepsy that is 
treated, used linear models with a fixed effect on the 
index of health­care access and quality and random 
effects on super­region. To determine the proportion of 
treated epilepsy where patients had not reported seizures 
in the previous year, we ran a linear regression with a 
fixed effect on the index of health­care access and quality. 
We split out the prevalence and incidence for these 
categories by sequentially applying the proportions to the 
prevalence and incidence of idiopathic epilepsy. The final 
category of less severe epilepsy was calculated as the 
overall less severe epilepsy category, excluding treated 
epilepsy with out seizures. Each one of the three severity 
categories has a specific disability weight, and years lived 
with disability (YLDs) were calculated as prevalence 
multiplied by the category­specific disability weight. 
Further details on the methodology are provided in the 
appendix.
Socio-demographic Index
The frequency and severity of epilepsy were also assessed 
with reference to the Socio­demographic Index (SDI), 
a composite measure developed to provide a comparable 
metric of overall socioeconomic development in each 
country and represented by the gross domestic product 
per capita, the average years of education in the population 
older than 15 years of age, and the total fertility rate.20
Risk estimation
Alcohol use was the only risk of the 84 risks included in 
GBD 2016 for which there was deemed to be sufficient 
evidence for a causal relationship with idiopathic epilepsy 
as an outcome. Population­attributable fractions were 
estimated using data for exposure, relative risk, and 
a theoretical­minimum exposure level. Additional details 
on calculations can be found in the GBD 2016 risk factor 
overview paper.15
Compilation of results
Years of life lost (YLLs) were calculated by multiplying 
the number of deaths at each age group by the remaining 
life expectancy at that age, which was derived from the 
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GBD standard life table.21 DALYs were then calculated by 
summing YLLs and YLDs. We propagated uncertainty at 
each step of the analytical process by sampling 1000 draws 
at each computational step. Uncertainty intervals (UIs) 
were defined as the 25th and 975th values of the ordered 
draws. The term rate was used to indicate the number of 
cases per 100 000 population, in keeping with the other 
GBD reports. Differences in rates and counts between 
1990 and 2016 are presented as significant if more than 
950 of 1000 draws were all negative, or all positive. The 
study is compliant with the Guidelines for Accurate and 
Transparent Health Estimates Reporting (appendix).
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or the 
writing of the report. All authors had full access to 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
In 2016, there were 45·9 million (95% UI 39·9–54·6) 
individuals with active epilepsy of idiopathic or second­
ary nature globally. Of these individuals, 24·0 million 
(20·4–27·7) had active idiopathic epilepsy. There were 
126 055 epilepsy­related deaths (118 632–135 517) and 
13·5 million DALYs (11·0–16·5; table 1), and there 
were 5·9 million (5·6–6·4) YLLs and 7·5 million 
(5·1–10·5) YLDs. Idiopathic epilepsy accounted for 
0·23% (0·22–0·25) of deaths and 0·56% (0·48–0·66) of 
DALYs from all causes. Global age­standardised mortality 
rates of idiopathic epilepsy were 1·74 per 100 000 popu­
lation (1·64–1·87; 1·40 per 100 000 population [1·23–1·54] 
for women and 2·09 per 100 000 population [1·96–2·25] 
for men). 
Globally, in 2016, there were 1·4 million (95% UI 
1·2–1·6) idiopathic epilepsy cases in men and 1·3 million 
(1·1–1·6) cases in women, with age­standardised inci­
dence rates of 38·9 per 100 000 person­years (32·7–45·7) 
for men and 37·1 per 100 000 person­years (30·8–44·1) for 
women. Between 1990 and 2016, there were no signifi­
cant changes in both age­standardised incidence rates 
(35·8 per 100 000 person­years [30·1–42·0] in 1990 and 
38·0 per 100 000 person­years [31·7–45·1] in 2016) and 
absolute number of people (2·1 million [1·7–2·4] in 1990 
and 2·8 million [2·3–3·3] in 2016) with incident idio­
pathic epilepsy. There were four times geographical vari­
ations in the age­standardised incidence rates of idiopathic 
epilepsy, with the highest rates observed in Ecuador 
(70·9 per 100 000 person­years [22·3–112·5]) and Mexico 
(56·0 per 100 000 person­years [41·0–72·0]) and the lowest 
rates in North Korea (17·0 per 100 000 person­years 
[5·7–28·2]) and China (19·7 per 100 000 person­years 
[14·2–25·6]).
Figure 1: Age-standardised prevalence per 100 000 of idiopathic epilepsy for both sexes, 2016
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In 2016, the global age­standardised prevalence of 
all active epilepsy (idiopathic and secondary) was 
621·5 per 100 000 population (95% UI 540·1–737·0). It 
varied from a low of 311·0 per 100 000 pop ulation 
(253·4–370·5) in Japan to a high of 1287·7 per 
100 000 population (754·4–1791·3) in Cape Verde. The 
prevalence of idiopathic epilepsy was 326·7 per 
100 000 population (278·4–378·1). The prevalence was 
329·3 per 100 000 population (280·3–381·2) in men and 
318·9 per 100 000 population (271·1–369·4) in women. 
Highest prevalence was found in eastern, western, and 
southern sub­Saharan Africa regions, central Asia, central 
and Andean Latin America, and southeast Asia (figure 1). 
Prevalence increased with age, with peaks at ages 
5–9 years (374·8 [280·1–490·0]) and at older than 80 years 
(545·1 [444·2–652·0]). Prevalence was similar in men and 
women (figure 2).
Global age­standardised DALY rates of idiopathic 
epilepsy were 182·6 per 100 000 population (95% UI 
149·0–223·5; 163·6 per 100 000 population [130·6–204·3] 
for women and 201·2 per 100 000 population [166·9–241·4] 
for men). The higher DALY rates in men were due to a 
higher YLL rate of 96·1 per 100 000 population (89·4–104·2) 
in men than in women (63·5 per 100 000 population 
[56·6–70·1]). Global age­standardised YLD rates in 2016 
were similar between men (105·1 per 100 000 population 
[70·8–145·5]) and women (100·1 per 100 000 population 
[68·0–138·6]). YLLs peaked at age under 5 years and at 
ages of 15–19 years and then decreased progressively with 
age (figure 3). YLDs peaked at 5–9 years of age, decreased 
until 40–49 years, and increased progressively to the oldest 
age group.
Between 1990 and 2016, age­standardised prevalence of 
idiopathic epilepsy did not change (6·0% [95% UI 
–4·0 to 16·7]), but a significant decrease was found in 
age­standardised mortality rates (24·5% [10·8 to 31·8]) 
and in age­standardised DALY rates (19·4% [9·0 to 27·6]). 
For further details on prevalence, incidence, deaths, 
DALYs, YLLs, and YLDs for both sexes, all ages, countries, 
and territories, please refer to the GBD Results Tool.
Counts for prevalent cases, deaths, and DALYs, and the 
corresponding percentage change in age­standardised 
rates between 1990 and 2016 of idiopathic epilepsy, 
varied across countries (table 1). There was a signifi­
cant differ ence in age­standardised prevalence of idio­
pathic epilepsy in 2016, ranging from 648·9 per 
100 000 population (95% UI 222·8–1012·3) in Botswana 
to 139·7 per 100 000 population (20·1–366·9) in the 
Central African Republic. The wide UIs, in part, reflect 
the heterogeneity of data sources for the estimates of all 
epilepsy. However, the largest source of uncertainty 
comes from modelling the sparse data on the proportion 
of all epilepsy that is idiopathic or secondary to other 
causes. No region, or even country, had a significant 
change in age­standardised prevalence between 1990 and 
2016. Age­standardised mortality rates of idiopathic 
epilepsy decreased significantly in 74 countries, mostly 
from western and central Europe, Australasia, high­
income North America, high­income Asia Pacific, Latin 
America, the Caribbean, and north Africa and the 
Middle East. By contrast, mortality rates increased in 
22 countries, predominantly from western sub­Saharan 
Africa, and occasionally also from Europe (Belgium, 
Denmark, Germany, Iceland, and Poland) and southeast 
Asia (Thailand). As a consequence of changes in 
mortality rates and subsequently YLL rates of idiopathic 
epilepsy, age­standardised DALY rates decreased signifi­
cantly in central Latin America, east Asia, south Asia, 
Figure 3: Global years lived with disability (YLDs) and years of life lost (YLLs) rates due to idiopathic epilepsy 
by age, 2016
Shaded areas show 95% uncertainty intervals.






















































Figure 2: Global prevalence of idiopathic epilepsy by age and sex, 2016
Shaded areas show 95% uncertainty intervals.
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and north Africa and the Middle East (table 1). However, 
in individual countries, a significant decrease was found 
only in the UK, Mexico, China, Bangladesh, and India.
Because of the wide UIs around prevalence, no country 
experienced a significant change between 1990 and 2016 
(table 1). By contrast, the reduction of age­standardised 
deaths varied by SDI quintiles, with large reductions in 
the three middle SDI quintiles, but no significant change 
in the low and high SDI quintiles. Expected values of 
age­standardised DALY rates decreased from an SDI 
value of 0·3 upward (figure 4). Most regions saw a steady 
decrease over time, with values close to the expected line. 
Rates in Oceania and western sub­Saharan Africa 
remained mostly unchanged over the estimation period. 
Rates in central Asia and southern sub­Saharan Africa 
rose to a peak halfway through the estimation period and 
then declined.
About two­thirds of the gap in age­standardised DALY 
rates between low SDI quintile countries (249·2 per 
100 000 population [95% UI 202·3–307·6]) and high 
SDI quintile countries (110·6 per 100 000 population 
[84·2–143·7]) were due to a difference in YLL rates 
(126·92 per 100 000 population [114·81–140·13] for low 
SDI countries and 34·05 per 100 000 population 
[32·48–36·28] for high SDI countries), and one­third was 
due to lesser severity of disease as measured in YLDs. 
Prevalence of idiopathic epilepsy was similar among the 
quintiles of SDI. In 2016, there was a strong gradient in 
the prevalence of idiopathic epilepsy by severity. Low 
SDI quintile countries had the highest age­standardised 
prevalence of severe epilepsy and the lowest age­
standardised prevalence of treated epilepsy without 
seizures, with the opposite being the case in high SDI 
countries (table 2).
The only risk quantified in GBD for idiopathic epi­
lepsy was alcohol use, estimated to be respons ible for 
18·9% (95% UI 14·6–23·1) of global DALYs from epi lepsy 
in men (7 524 103·60 [6 254 535·71–9 024 594·20]) and 
8·2% (5·8–10·5) in women (5 968 147·15 [4 760 417·45–
7 452 692·07]).
Discussion
Between 1990 and 2016, a significant reduction was 
observed in the mortality rate in people with idiopathic 
epilepsy and, to a lesser extent, a reduction was found in 
DALY rates, a comprehensive measure of the burden of 
the disease, when adjusted for age. This finding probably 
reflects improvements in access to treatment leading to a 
lower risk of death and lesser severity of the disease. 
Nevertheless, a substantial treat ment gap remains (due 
to insufficient financial resources, misconceptions, and 
stigma22) that can explain the larger proportion of severe 
epilepsies and higher case fatality when comparing high 
SDI with middle and low SDI countries.
Our estimate of 45·9 million cases of idiopathic active 
and secondary epilepsy in 2016 is higher than the 
32·7 million cases reported from a meta­analysis of 
65 prevalence studies,7 but it seems that the estimate of 
the number of cases of active epilepsy in rural populations 
in low­income countries was reported as 17 million in the 
meta­analysis, whereas our interpret ation of the results is 
that it should have been 37 million. Furthermore, it is not 
clearly stated for which year the estimate was made in the 
meta­analysis. However, similar to findings from that 
meta­analysis, large variations were observed in the 
prevalence of epilepsy in this study, but there was no clear 
pattern by development status or by location. This finding 
raises the question of how much of the variation we 
estimated between countries is real or an artifact of 
measurement error we have been unable to control for. 
The unknown cause of epilepsy, apart from an association 
with alcohol use, makes it difficult to fit estimates to 
sparse and heterogeneous data.
In 2016, epilepsy accounted for more than 13 million 
DALYs, that is 0·56% of total DALYs globally. The 
numbers are significantly higher than the projected 
estimates from WHO (7·4 million),5 but the proportion 
of total DALYs attributable to epilepsy in the WHO report 
(0·50%) was almost identical despite multiple measure­
ment differ ences making results incomparable. In that 
report, epilepsy was defined in accordance with the 2005 
ILAE and International Bureau for Epilepsy definition as 
Figure 4: Age-standardised disability-adjusted life-year (DALY) rates for idiopathic epilepsy in 21 GBD regions 
by Socio-demographic Index, 1990–2016
Age-standardised DALY rates are plotted for 21 world regions between 1990 and 2016 against their 
Socio-demographic Index values. Points from left to right represent the values from 1990 to 2016. The black line 
represents the predicted values based on a regression of all country values for all years.
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a disorder of the brain characterised by an enduring 
predisposition to generate epileptic seizures.23 This 
definition is in keeping with the definition used in the 
present study. Other population­based studies addressed 
the burden of epilepsy using the DALY metrics. These 
studies were done in China,24 India,25 and South Africa.26 
However, the results of these studies cannot be compared 
with ours because of the different methodology and the 
regional perspective.
Apart from the major changes in how DALYs are 
defined since GBD 2010 (no more discounting or age­
weighting, a prevalence instead of incidence approach to 
measuring non­fatal outcomes, and disability weights 
derived from large population surveys rather than a small 
panel of health experts), the largest difference is that in 
the past decade, we have developed statistical models that 
can evaluate all available epidemiological evidence rather 
than relying on an analyst to determine a single data 
source to describe prevalence or incidence in a country.
Variables such as race or ethnicity and socioeconomic 
level might be also inter­related. Our and others’ findings6 
support the concept that epilepsy and poverty might have 
a bidirectional association. The inverse association 
between the burden of epilepsy and sociodemographic 
status is in line with other neurological disorders8 and 
with published reports from low­income countries 
and from people with low incomes in high­income 
countries.27–29 Inequalities in health might also vary 
among members of the same population.30 Low socio­
economic status is also associated with risk factors for 
epilepsy.31 We should, however, argue that if we find an 
important link between the development status of 
countries and epilepsy outcomes, it is likely that much 
larger variation in outcomes exists at the individual level 
depending on a person’s socioeconomic attributes.
The major strength of this study is the worldwide 
assessment of the burden of all major diseases, including 
epilepsy, using the same methodology and modelling 
measures. Another strength is the continuous refinement 
of the available data through input from new original 
sources and the use of more sophisticated statistical 
methods as these develop. There are, however, some 
general and disease­specific limitations. First, as original 
epidemiological data were not available for all countries, 
Bayesian statistical models were used to estimate deaths 
and disease prevalence for countries with missing 
information. The inclusion of data sources from new 
original studies in countries for which no data were 
available in a previous iteration of GBD can lead to more 
precise estimates that might vary considerably from 
previous predicted values. The annual updates of GBD 
provide an opportunity to improve on estimates as new 
data or new methods become available. Second, the 
disability weights used for the calculation of YLDs might 
not be uniform across populations and sociodemographic 
levels. However, population surveys in nine countries did 
not find systematic variation in disability weights across 
populations or within the same population as a function 
of education.17,32,33 Third, the 95% UI used to define the 
precision of the estimates are wide, reflecting the overall 
uncertainty of the estimates and, as a consequence, 
limiting the ability to find differences across countries. 
This finding can explain why few countries showed a 
significant change in DALY rates. The main source of 
uncertainty around the incidence and prevalence 
estimates of idiopathic epilepsy comes from the sparse 
and heterogeneous data about the proportion of people 
with idiopathic as opposed to secondary epilepsy and, for 
idiopathic epilepsy, on the distribution of (presumed) 
genetic and cryptogenic forms. Likewise, deaths as part of 
idiopathic epilepsy might include deaths of people with 
secondary epilepsy. Further uncertainty comes from our 
definition of severity and the estimates of the proportion 
of people with severe epilepsy, people with less severe 
epilepsy, and those with no seizures while on treatment. A 
third source of uncertainty for the YLD estimates comes 
Idiopathic epilepsy Seizure-free, treated idiopathic 
epilepsy
Less severe idiopathic epilepsy Severe epilepsy





65·9 (50·6–83·0) 3·1 (1·8–4·8) 125·5 
(98·3–155·1)
30·7 (19·4–45·0) 135·3 
(103·3–170·8)
68·7 (45·0–97·8)




137·9 (99·7–177·8) 6·5 (3·6–10·0) 63·3 
(44·9–87·2)
15·4 (9·3–23·6) 108·0 
(72·7–153·8)
54·6 (31·7–84·4)




83·4 (57·0–112·5) 3·9 (2·2–6·3) 95·4 
(65·3–132·7)
23·4 (13·7–36·5) 116·8 
(75·2–166·6)
59·3 (34·3–91·1)




65·5 (46·4–87·4) 3·1 (1·7–5·0) 143·1 
(109·5–184·6)
35·1 (21·8–51·9) 139·6 
(102·9–182·0)
71·2 (44·2–102·5)




34·5 (22·5–49·0) 1·6 (0·9–2·8) 153·9 
(110·1–200·8)
37·3 (22·3–56·8) 138·2 
(94·6–190·0)
69·5 (41·4–105·9)




15·1 (7·4–25·8) 0·7 (0·3–1·4) 131·0 
(83·7–191·7)
31·8 (17·6–53·7) 179·3 
(123·5–250·2)
90·0 (53·5–138·3)
95% uncertainty intervals are in parentheses. Severe epilepsy is defined as more than one seizure per month; less severe epilepsy is defined as those who have 1–11 seizures per year or did not have a seizure in the 
past year while untreated but still fulfilling criteria of active epilepsy. SDI=Socio-demographic Index. YLDs=years lived with disability.
Table 2: Age-standardised prevalence per 100 000 population and YLDs of idiopathic epilepsy in 2016, and its sequelae globally and by SDI quintiles
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from the wide uncertainty bounds around the disability 
weights. New data collection on these various proportions 
that determine the sequelae of epilepsy would have the 
greatest bearing on reducing UIs. Fourth, epilepsy is 
correlated with somatic and psychiatric comorbidities34 
and injuries,35 as well as a host of diseases associated with 
stigma and poverty.36 Here, the correction for comorbidity 
was based on the assumption that diseases and their 
sequelae are independent. Future improve ments of the 
GBD modelling should include dependent comorbidity. 
Fifth, the use of medical claims data could introduce a 
systematic bias as people who are not under treatment or 
are excluded from health insurance would not be counted. 
For the 3 years of claims data from the USA, we applied a 
correction based on a comparison with representative 
survey data. In coming years, we hope to include claims 
data from other countries and more comprehensive 
claims data from the USA that are less biased towards 
individuals with private health insurance only. The 
challenge will be to find represen tative survey data in 
those countries to make credible adjustments. Sixth, the 
peak in DALY rates in southern sub­Saharan Africa 
coincides with the peak in deaths as a result of HIV or 
AIDS in 2005 and suggests that despite an effort to correct 
deaths miscoded to non­HIV causes in the South African 
vital registration data, we might have left some remaning 
deaths that should have been reassigned to HIV or AIDS. 
However, even if the peak is an artifact, these regions still 
have much higher than expected DALY rates for idiopathic 
epilepsy. The reason for the recorded increase and then 
decrease in deaths in vital registration data from central 
Asia is less clear. Seventh, the higher mortality rate of 
idiopathic epilepsy in some western European countries 
than in low­income and middle­income countries cannot 
be easily explained and might reflect differences in cause 
of death certification practices. Last, epilepsy in this report 
is defined by having at least two unprovoked seizures and 
is in contrast with the recent ILAE definition that includes 
a single unprovoked seizure judged at high risk of 
relapse.37 However, almost all published reports included 
patients with recurrent seizures and perhaps the inclusion 
of individuals with single seizures would increase the 
burden of the disease.
In conclusion, our findings have important impli­
cations for health service planning. The decrease in death 
and DALY rates in patients with epilepsy between 1990 
and 2016 is encouraging, but the changes varied across 
geographical areas and, where data were available, within 
countries. Furthermore, changes were linked to the 
sociodemographic development status, which should 
prompt more action in economically deprived areas. The 
success of reducing the burden of idiopathic epilepsy 
relies mostly on access to treatment. Health service 
planners and providers also need to be aware that patients 
with epilepsy are more often poor and marginalised 
because of stigma, requiring a greater effort to reach 
them than might be the case for most other diseases.
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